Next Article in Journal
Insolubilization of Chestnut Shell Pigment for Cu(II) Adsorption from Water
Next Article in Special Issue
Self-resistance in Streptomyces, with Special Reference to β-Lactam Antibiotics
Previous Article in Journal
NMR Study on the Inclusion Complexes of β-Cyclodextrin with Isoflavones
Previous Article in Special Issue
Large Scale Screening of Ethnomedicinal Plants for Identification of Potential Antibacterial Compounds
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Molecules 2016, 21(4), 268;

The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity

National Center of Excellence in Physical Chemistry, University of Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan
Department of Chemistry, Islamia College University Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan
Author to whom correspondence should be addressed.
Academic Editor: Peter J. Rutledge
Received: 23 December 2015 / Revised: 8 February 2016 / Accepted: 15 February 2016 / Published: 28 March 2016
Full-Text   |   PDF [2378 KB, uploaded 28 March 2016]   |  


Quinolones are broad-spectrum synthetic antibacterial drugs first obtained during the synthesis of chloroquine. Nalidixic acid, the prototype of quinolones, first became available for clinical consumption in 1962 and was used mainly for urinary tract infections caused by Escherichia coli and other pathogenic Gram-negative bacteria. Recently, significant work has been carried out to synthesize novel quinolone analogues with enhanced activity and potential usage for the treatment of different bacterial diseases. These novel analogues are made by substitution at different sites—the variation at the C-6 and C-8 positions gives more effective drugs. Substitution of a fluorine atom at the C-6 position produces fluroquinolones, which account for a large proportion of the quinolones in clinical use. Among others, substitution of piperazine or methylpiperazine, pyrrolidinyl and piperidinyl rings also yields effective analogues. A total of twenty six analogues are reported in this review. The targets of quinolones are two bacterial enzymes of the class II topoisomerase family, namely gyrase and topoisomerase IV. Quinolones increase the concentration of drug-enzyme-DNA cleavage complexes and convert them into cellular toxins; as a result they are bactericidal. High bioavailability, relative low toxicity and favorable pharmacokinetics have resulted in the clinical success of fluoroquinolones and quinolones. Due to these superior properties, quinolones have been extensively utilized and this increased usage has resulted in some quinolone-resistant bacterial strains. Bacteria become resistant to quinolones by three mechanisms: (1) mutation in the target site (gyrase and/or topoisomerase IV) of quinolones; (2) plasmid-mediated resistance; and (3) chromosome-mediated quinolone resistance. In plasmid-mediated resistance, the efflux of quinolones is increased along with a decrease in the interaction of the drug with gyrase (topoisomerase IV). In the case of chromosome-mediated quinolone resistance, there is a decrease in the influx of the drug into the cell. View Full-Text
Keywords: quinolones; analogues; gyrase; topoisomerase IV; resistance quinolones; analogues; gyrase; topoisomerase IV; resistance

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Naeem, A.; Badshah, S.L.; Muska, M.; Ahmad, N.; Khan, K. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity. Molecules 2016, 21, 268.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top